Tianyin Appoints Dr. James Jiayuan Tong as Chief Financial Officer and Chief Business & Development Officer
Prior to joining Tianyin, Dr. Tong was the Head of China HealthcareInvestment Banking at ROTH Capital Partners, Newport Beach, CA. He initiallyjoined ROTH as an equity research analyst, spearheading ROTH's effort in Chinahealthcare universe, covering a series of U.S.-listed Chinese pharmaceutical,biotech, medical devices and drug retail businesses. Prior to that, Dr. Tongwas a biotechnology analyst at Rodman & Renshaw, New York, covering biotechentities focusing on molecular diagnostics and cures for Alzheimer's disease,multiple sclerosis and cancer. Before his Wall Street career, Dr. Tong wasPrincipal Investigator at Marine Biological Laboratory (MBL) sponsored byGrass Foundation at Woods Hole, MA and a Senior Research Fellow at Universityof California, Irvine (UCI).
Dr. Tong was awarded Ph.D. in Neurobiology and Behavior from Cold SpringHarbor Laboratory / Stony Brook University Neuroscience program. He developedan innovative method to significantly extend life spans of animals based onhis work on mitochondria, aging and learning disorders in Neurofibromatosis-1(NF1) disease. He published three first-authored Nature articles andcurrently holds two patents. Dr. Tong received his medical degree from PekingUniversity Health Science Center.
"We are excited that Dr. Tong joins us as our Chief Financial Officer andChief Business & Development Officer," stated Dr. Guoqing Jiang, Tianyin'sChief Executive Officer. "His responsibilities as CFO, CBDO, and board memberwill further strengthen Tianyin's capabilities in growth strategy execution,business & development, financial management and corporate communications. Atthe dawn of the rapid expansion of China healthcare industry, fueled by theeconomic growth and the healthcare reform in China, Tianyin is poised for thesustainable growth through further pipeline enrichment and capacityexpansion."
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional ChineseMedicine ("TCM") in China. It was established in 1994 and acquired by thecurrent management team in August 2003. It has a comprehensive productportfolio of 39 products, 22 of which are listed in the highly selectiveNational Medicine Catalog of the National Medical Insurance program. Tianyinowns and operates two GMP manufacturing facilities and an R&D platformsupported by leading Chinese academic institutions. The Company has a pipelineof 17 pharmaceutical products pending approval. Tianyin has an extensivenationwide distribution network throughout China with a sales force of 720salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with atotal of 1,365 employees. For more information about Tianyin, please visithttp://www.tianyinpharma.com .
Safe Harbor Statement
The Statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.For more information, please contact: For the Company: James Jiayuan Tong, M.D. Ph.D. CFO & CBDO Tel: +1-949-350-6999 Email: Dr.Tong.TPI@gmail.com Investors: Mr. Matthew Hayden, HC International Tel: +1-561-245-5155 Email: firstname.lastname@example.org Web: http://www.hcinternational.net
SOURCE Tianyin Pharmaceutical Co., Inc.
You May Also Like